Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$78.01
▲ $0.22 (+0.3%)
Market data updated: 09/19 10:27 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$4.30B
Day Range
$76.78 - $78.44
52-Week Range
$48.82 - $85.76
Beta
—
Next Earnings
03.11.2026
Support
$74.67
Resistance
$85.76
LIVN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+39.5% (1Y)
Strengths: 9/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Free cash flow growth
Free cash flow growth: 27.5%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $65.02 vs. price $78.01 (-16.7%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
47
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
51
Quality
63
Value
38
Momentum
29
Risk
48
Sentiment
86
Fundamental
45
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **LivaNova PLC** has centered on its financial performance and investor sentiment, with analysts highlighting its **affordable growth status**, strong earnings growth, and fair valuation. The company is set to present at major healthcare conferences in September, while Piper Sandler raised its price target to $90, signaling optimism. Technical analyses also noted potential breakout opportunities, though some reports cautioned about valuation risks. No major operational or product-related news was prominently featured.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about LivaNova PLC. News trend score: 86. Reason: 9 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
22
🎯 Conviction (vs. Emotion)
42
Psychology
24
Fundamentals
45
Technical
29
Valuation
38
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
-1%
Market Narrative
60
Fundamental Reality
42
Narrative Gap
+18
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests a dominant herd-driven dynamic, where LIVN’s underperformance relative to peers (-1.5% vs. -0.6%) may be prompting traders to align with broader sector trends. Euphoria and overconfidence coexist, fueled by strong momentum (+3.2% ROC) and a 24% premium to DCF, indicating investors may be ignoring fundamental growth lags (-4.8% EPS). The narrative gap (32 points) hints at a disconnect between optimistic pricing and underlying fundamentals. The key question is whether the herd will sustain momentum or pivot if peers recover.
Updated: 09/09/2026, 06:40 AM
What could change this?
👥 What the crowd believes
"LivaNova PLC remains a 'Hold' with a maintained price target of $68/share, reflecting limited risk-adjusted upside."
"Piper Sandler analyst raises LivaNova price target from $87 to $90."
"LivaNova (LIVN) passes strong growth & technical setup screen with 15.66% EPS growth."
"Ahmet Tezel, Chief Innovation Officer, offloaded $876K in LivaNova stock."
📈 15D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 88/100
🔴 Weakest match
Thorstein Veblen — 21/100
🗣️ Why do they disagree?
The scores for LIVN span from Nelson’s strong 84 down to Veblen’s 21, showing how each historical framework emphasizes different factors. Based on Nelson’s documented principles, the model estimates a favorable cycle position, while Housel and Mackay, who value quiet compounding and crowd sentiment, rate the stock moderately positive; in contrast, Lynch, Schwager, and Livermore, who focus on growth‑at‑a‑reasonable‑price and trend alignment, find the stock fails their key thresholds. Value‑oriented investors like Graham and Graham‑Enterprising, using defensive safety‑margin criteria, assign very low scores, and Veblen flags the company as growth pursued for its own sake. Mid‑range thinkers such as Fisher, Loeb, Marks, and the efficient‑market view see a mixed picture—solid but not exceptional quality, moderate risk, and limited advantage over a broad index.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 88
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 73
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 65
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 61
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 57
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 53
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 51
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 50
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 49
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 46
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 42
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 39
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 39
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 25
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 25
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 8 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
A trading range after an advance, but still without clear (volume-based) confirmation of a distribution phase.
Low confidence
$74.67
Range Bottom
$85.76
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
67.7%
Operating Margin
14.4%
Net Margin
-17.5%
EBITDA Margin
14.4%
ROE
-20.2%
ROA
-9.3%
ROIC
—
EPS
-$4.45
Cash
$635.55M
Total Debt
$376.06M
Current Ratio
1.36
Debt/Equity
0.31
How is Fair Value calculated? →
Current Price
$78.01
Estimated Fair Value (DCF)
$65.02
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-16.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
10.8%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.8% | $191.94M | $176.09M |
| 2 | 8.7% | $208.64M | $175.61M |
| 3 | 6.6% | $222.48M | $171.79M |
| 4 | 4.6% | $232.63M | $164.80M |
| 5 | 2.5% | $238.45M | $154.98M |
Base FCF (last actual year)
$173.29M
Terminal Value
$3.76B
Present Value of Terminal Value
$2.44B
Enterprise Value
$3.29B
Net Debt
$-259.49M
Equity Value
$3.55B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$22.00
Tangible Book Value per Share (Tangible NAV)
$3.25
Sentiment based on basic keywords (not AI) — 9 positive, 8 neutral, 3 negative out of the last 20 articles.
Benzinga · 15.9.2026
MT Newswires · 14.9.2026
SeekingAlpha · 14.9.2026
Yahoo · 11.9.2026
Motley Fool · 11.9.2026
ChartMill · 9.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
ChartMill · 7.9.2026
Yahoo · 3.9.2026
Business Wire · 3.9.2026
Benzinga · 2.9.2026
SeekingAlpha · 25.8.2026
SeekingAlpha · 24.8.2026
ChartMill · 18.8.2026
Yahoo · 17.8.2026
Yahoo · 17.8.2026
Benzinga · 14.8.2026
Simply Wall St. · 12.8.2026
Yahoo · 12.8.2026
LivaNova PLC (LIVN) currently has a StockIQ AI score of 47/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
LIVN currently scores 47/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, LIVN's estimated fair value is $65.02, which is 16.7% below the current price of $78.01. This is one valuation model among several signals in the fair-value category, not a price target.
LIVN's technical score is 29/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Free cash flow growth: 27.5%; Operating margin is stable or improving over time; Debt/equity: 0.31.
Based on the real signals StockIQ computed: Estimated fair value: $65.02 vs. price $78.01 (-16.7%); Net margin: -17.5% (negative); Calmar: 0.23 (3y annualized return 10.8% / max drawdown 47.2%).
StockIQ has no recorded dividend payment history for LIVN.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 5 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Bianchi Francesco | Open Market Sale | 10.9.2026 | 3,500 | -3,500 | $78.01 |
| Story Brooke | Open Market Sale | 4.9.2026 | 2,300 | -2,300 | $81.42 |
| Bianchi Francesco | Open Market Sale | 31.8.2026 | 1,650 | -1,650 | $79.72 |
| Tezel Ahmet | Tax Withholding in Shares | 11.8.2026 | 8,765 | -1,428 | $77.86 |
| Tezel Ahmet | Exercise of Derivative Securities | 11.8.2026 | 12,691 | -12,692 | — |
| Tezel Ahmet | Disposition to the Company | 11.8.2026 | 10,193 | -8,589 | $77.86 |
| Tezel Ahmet | Open Market Sale | 11.8.2026 | 6,090 | -2,675 | $77.74 |
| Tezel Ahmet | Exercise of Derivative Securities | 11.8.2026 | 18,782 | +12,692 | $52.68 |
| Tezel Ahmet | Exercise of Derivative Securities | 11.8.2026 | 12,692 | -12,692 | — |
| Tezel Ahmet | Open Market Sale | 11.8.2026 | 2,675 | -2,675 | $77.74 |
| Tezel Ahmet | Tax Withholding in Shares | 11.8.2026 | 1,428 | -1,428 | $77.86 |
| Tezel Ahmet | Exercise of Derivative Securities | 11.8.2026 | 12,692 | +12,692 | $52.68 |
| Tezel Ahmet | Disposition to the Company | 11.8.2026 | 8,589 | -8,589 | $77.86 |
| Zurbay Donald | Grant/Award from Employer | 15.6.2026 | 2,383 | +2,383 | — |
| Zurbay Donald | Exercise of Derivative Securities | 15.6.2026 | 2,560 | -2,560 | — |
| Zurbay Donald | Tax Withholding in Shares | 15.6.2026 | 308 | -308 | $79.70 |
| Zurbay Donald | Exercise of Derivative Securities | 15.6.2026 | 2,560 | +2,560 | — |
| Story Brooke | Grant/Award from Employer | 15.6.2026 | 2,383 | +2,383 | — |
| Story Brooke | Exercise of Derivative Securities | 15.6.2026 | 4,042 | -4,042 | — |
| Story Brooke | Tax Withholding in Shares | 15.6.2026 | 486 | -486 | $79.70 |
| Story Brooke | Exercise of Derivative Securities | 15.6.2026 | 4,042 | +4,042 | — |
| Enxing Seng Stacy | Grant/Award from Employer | 15.6.2026 | 2,383 | +2,383 | — |
| Enxing Seng Stacy | Exercise of Derivative Securities | 15.6.2026 | 4,042 | -4,042 | — |
| Enxing Seng Stacy | Tax Withholding in Shares | 15.6.2026 | 486 | -486 | $79.70 |
| Enxing Seng Stacy | Exercise of Derivative Securities | 15.6.2026 | 4,042 | +4,042 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,987,757 shares short as of 2026-08-31 · vs. 4,143,484 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
63.5% of trading volume this week was short selling, vs. 75.5% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology